Progress in aldosteronism: A review of the prevalence of primary aldosteronism in pre-hypertension and hypertension

European Journal of Endocrinology

Volumn 172, Issue 5, 2015, Pages R191-R203

  Piaditis, George ^a   Markou, Athina ^a   Papanastasiou, Labrini ^a   Androulakis, Ioannis I ^a,b   Kaltsas, Gregory ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CAPTOPRIL; CORTICOTROPIN; DEXAMETHASONE; FLUDROCORTISONE;

CAPTOPRIL TEST; COMPUTER ASSISTED TOMOGRAPHY; CORTICOTROPIN RELEASE; DEXAMETHASONE SUPPRESSION TEST; DIASTOLIC BLOOD PRESSURE; ENDOCRINE FUNCTION TEST; FLUDROCORTISONE DEXAMETHASONE SUPPRESSION TEST; FLUDROCORTISONE SUPPRESSION TEST; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HORMONAL REGULATION; HUMAN; HYPERTENSION; LOW DOSE DEXAMETHASONE SUPPRESSION TEST; POST DEXAMETHASONE SALINE INFUSION TEST; PREHYPERTENSION; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALINE INFUSION TEST; SALT LOADING; SYSTOLIC BLOOD PRESSURE; COMPLICATION; GENETICS; HYPERALDOSTERONISM; METABOLISM;

ADRENOCORTICOTROPIC HORMONE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; PREHYPERTENSION; PREVALENCE;

EID: 84929512595     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0537     Document Type: Review

References (100)

1. Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ & KlemmSA. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: Adrenal hyperplasia) or lowrenin essential hypertension. Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension 1987 5 S103-S106.
2. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N & Slater GJ. Diagnosis and management of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System 2001 2 156-169. (doi:10.3317/jraas.2001.022)
3. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology 2006 48 2293-2300. (doi:10.1016/j.jacc.2006.07.059)
4. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. Journal of Clinical Endocrinology and Metabolism 2004 89 4221-4226. (doi:10.1210/jc.2003-032179)
5. Gordon RD, Stowasser M, Tunny TJ, Klemm SA & Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clinical and Experimental Pharmacology & Physiology 1994 21 315-318. (doi:10.1111/j.1440-1681.1994.tb02519.x)
6. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. Journal of Clinical Endocrinology and Metabolism 2000 85 1863-1867. (doi:10.1210/jcem. 85.5.6596)
7. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C & Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'nonselectivee screening of hypertensive patients. Journal of Hypertension 2003 21 2149-2157. (doi:10.1097/00004872-200311000-00025)
8. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F & Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Journal of Clinical Endocrinology and Metabolism 2004 89 1045-1050. (doi:10.1210/jc.2003-031337)
9. Douma S, Petidis K, DoumasM, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K & Zamboulis C. Prevalence of primary hyperaldosteronismin resistant hypertension: A retrospective observational study. Lancet 2008 371 1921-1926. (doi:10.1016/ S0140-6736(08)60834-X)
10. Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, Volzke H, Beuschlein F, Seissler J, Rettig R, Felix SB et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. European Journal of Endocrinology 2012 167 7-15. (doi:10.1530/EJE-11-1013)
11. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T & Kimura G. Cardiovascular complications in patients with primary aldosteronism. American Journal of Kidney Diseases 1999 33 261-266. (doi:10.1016/S0272-6386(99)70298-2)
12. Farquharson CA & Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clinical Science 2002 103 425-431.
13. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F & Pessina AC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013 62 62-69. (doi:10.1161/ HYPERTENSIONAHA.113.01316)
14. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN & Conlin PR. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. Journal of Human Hypertension 2006 20 129-136. (doi:10.1038/sj.jhh.1001948)
15. Young WF. Primary aldosteronism: renaissance of a syndrome. Clinical Endocrinology 2007 66 607-618. (doi:10.1111/j.1365-2265.2007. 02775.x)
16. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH & Gordon RD. Laboratory investigation of primary aldosteronism. Clinical Biochemist. Reviews 2010 31 39-56.
17. Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, Prevoli A, Tsiavos V, Papanastasiou L, Zografos G et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension. Journal of Clinical Endocrinology and Metabolism 2013 98 1409-1416. (doi:10.1210/jc.2012-3353)
18. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J & Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clinical Endocrinology 2010 73 1-15. (doi:10.1111/j.1365-2265.2009.03689.x)
19. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F & Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism 2005 16 114-119. (doi:10.1016/j.tem.2005.02.007)
20. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr & Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 3266-3281. (doi:10.1210/jc.2008-0104)
21. Schirpenbach C & Reincke M. Screening for primary aldosteronism. Best Practice & Research. Clinical Endocrinology & Metabolism 2006 20 369-384. (doi:10.1016/j.beem.2006.07.007)
22. Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R et al. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2012 97 1606-1614. (doi:10.1210/jc.2011-2830)
23. Nanba K, Tamanaha T, Nakao K, Kawashima ST, Usui T, Tagami T, Okuno H, Shimatsu A, Suzuki T & Naruse M. Confirmatory testing in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2012 97 1688-1694. (doi:10.1210/jc.2011-2504)
24. Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, Mosso L, Marafetti L, Veglio F & Maccario M. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2006 91 2618-2623. (doi:10.1210/ jc.2006-0078)
25. Mulatero P, Milan A, Williams TA & Veglio F. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovascular & Hematological Agents in Medicinal Chemistry 2006 4 75-91. (doi:10.2174/187152506775268776)
26. Westerdahl C, Bergenfelz A, Isaksson A & Valdemarsson S. Captopril suppression: limitations for confirmation of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System 2011 12 326-332. (doi:10.1177/1470320310390405)
27. Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ & Stowasser M. Seated saline suppression testing for the diagnosis of primary aldosteronism: A preliminary study. Journal of Clinical Endocrinology and Metabolism 2014 99 2745-2753. (doi:10.1210/jc. 2014-1153)
28. Mulatero P, Monticone S, Rainey WE, Veglio F & Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nature Reviews. Endocrinology 2013 9 104-112. (doi:10.1038/nrendo.2012.230)
29. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S & Lalouel JM. A chimaeric 11b-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992 355 262-265. (doi:10.1038/355262a0)
30. Beuschlein F. Regulation of aldosterone secretion: from physiology to disease. European Journal of Endocrinology 2013 168 R85-R93. (doi:10.1530/EJE-13-0263)
31. Al-Salameh A, Cohen R & Desailloud R. Overview of the genetic determinants of primary aldosteronism. Application of Clinical Genetics 2014 7 67-79. (doi:10.2147/TACG.S45620)
32. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ et al. KC channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011 331 768-772. (doi:10.1126/science.1198785)
33. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics 2013 45 440-442. (doi:10.1038/ng.2550)
34. Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW et al. Somatic and germline CACNA1D calcium channel mutations in aldosteroneproducing adenomas and primary aldosteronism. Nature Genetics 2013 45 1050-1054. (doi:10.1038/ng.2695)
35. Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nature Genetics 2013 45 1055-1060. (doi:10.1038/ng.2716)
36. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. PNAS 2012 109 2533-2538. (doi:10.1073/pnas.1121407109)
37. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012 59 592-598. (doi:10.1161/ HYPERTENSIONAHA.111.186478)
38. Stowasser M. Primary aldosteronism and potassium channel mutations. Current Opinion in Endocrinology, Diabetes, and Obesity 2013 20 170-179. (doi:10.1097/MED.0b013e32835ef2fd)
39. Xekouki P,HatchMM, LinL,RodrigodeA,AzevedoM,de laLuz SierraM, Levy I, Saloustros E, Moraitis A, Horvath A et al. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: An infrequent genetic cause of Connes syndrome. Endocrine-Related Cancer 2012 19 255-260. (doi:10.1530/ERC-12-0022)
40. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Okada S, Rokutanda N, Takata D et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 2012 97 1311-1319. (doi:10.1210/jc.2011-2885)
41. Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, Strom TM, Monticone S, Amar L, Meatchi T et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 2014 64 354-361. (doi:10.1161/HYPERTENSIONAHA.114.03419)
42. Gomez-Sanchez CE, Rossi GP, Fallo F & Mannelli M. Progress in primary aldosteronism: present challenges and perspectives. Hormone and Metabolic Research 2010 42 374-381. (doi:10.1055/ s-0029-1243619)
43. van Leeuwen N, Caprio M, Blaya C, Fumeron F, Sartorato P, Ronconi V, Giacchetti G, Mantero F, Fernandes-Rosa FL, Simian C et al. The functional c.-2GOC variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels. Hypertension 2010 56 995-1002. (doi:10.1161/HYPERTENSIONAHA.110.155630)
44. Fuchs-Hammoser R, Schweiger M & Oelkers W. The effect of chronic low-dose infusion of ACTH (1-24) on renin, renin-substrate, aldosterone and other corticosteroids in sodium replete and deplete man. Acta Endocrinologica 1980 95 198-206.
45. Arvat E, Di VL, Lanfranco F, Maccario M, Baffoni C, Rossetto R, Aimaretti G, Camanni F & Ghigo E. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. Journal of Clinical Endocrinology and Metabolism 2000 85 3141-3146. (doi:10.1210/jcem. 85.9.6784)
46. Hattangady NG, Olala LO, Bollag WB & Rainey WE. Acute and chronic regulation of aldosterone production. Molecular and Cellular Endocrinology 2012 350 151-162. (doi:10.1016/j.mce.2011.07.034)
47. Xing Y, Parker CR, Edwards M & Rainey WE. ACTH is a potent regulator of gene expression in human adrenal cells. Journal of Molecular Endocrinology 2010 45 59-68. (doi:10.1677/JME-10-0006)
48. Lin L, Hindmarsh PC, Metherell LA, Alzyoud M, Al-Ali M, Brain CE, Clark AJ, Dattani MT & Achermann JC. Severe loss-of-function mutations in the adrenocorticotropin receptor (ACTHR, MC2R) can be found in patients diagnosed with salt-losing adrenal hypoplasia. Clinical Endocrinology 2007 66 205-210. (doi:10.1111/j.1365-2265. 2006.02709.x)
49. Reincke M, Beuschlein F, Latronico AC, Arlt W, Chrousos GP & Allolio B. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Clinical Endocrinology 1997 46 619-626. (doi:10.1046/j. 1365-2265.1997.1991009.x)
50. Arnaldi G, Gasc JM, de Keyzer Y, Raffin-Sanson ML, Perraudin V, Kuhn JM, Raux-Demay MC, Luton JP, Clauser E & Bertagna X. Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 2029-2035. (doi:10.1210/jcem. 83.6.4873)
51. LampronA,BourdeauI,Oble S,GodboutA, SchurchW,ArjaneP,HametP & Lacroix A. Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldosteronoma. Journal of Clinical Endocrinology and Metabolism 2009 94 750-756. (doi:10.1210/jc.2008-1340)
52. Kem DC, Weinberger MH, Gomez-Sanchez C, Kramer NJ, Lerman R, Furuyama S & Nugent CA. Circadian rhythm of plasma aldosterone concentration in patients with primary aldosteronism. Journal of Clinical Investigation 1973 52 2272-2277. (doi:10.1172/JCI107414)
53. Hoefnagels WH, Drayer JI, Smals AG, Benraad TJ & Kloppenborg PW. Nocturnal, daytime, and postural changes of plasma aldosterone before and during dexamethasone in adenomatous and idiopathic aldosteronism. Journal of Clinical Endocrinology and Metabolism 1980 51 1330-1334. (doi:10.1210/jcem-51-6-1330)
54. Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F & ReinckeM. Screening for membrane hormone receptor expression in primary aldosteronism. European Journal of Endocrinology 2009 160 443-451. (doi:10.1530/EJE-08-0711)
55. Androulakis II, Kaltsas GA, Kollias GE, Markou AC, Gouli AK, Thomas DA, Alexandraki KI, Papamichael CM, Hadjidakis DJ & Piaditis GP. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. Journal of Clinical Endocrinology and Metabolism 2014 99 2754-2762. (doi:10.1210/jc.2013-4064)
56. Luger A, Deuster PA, Debolt JE, Loriaux DL & Chrousos GP. Acute exercise stimulates the renin-angiotensin-aldosterone axis: Adaptive changes in runners. Hormone Research 1988 30 5-9. (doi:10.1159/ 000181017)
57. Luger A, Deuster PA, Kyle SB, Gallucci WT, Montgomery LC, Gold PW, Loriaux DL & Chrousos GP. Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training. New England Journal of Medicine 1987 316 1309-1315. (doi:10.1056/NEJM198705213162105)
58. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, Nikkila H & White PC. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998 97 569-575. (doi:10.1161/01.CIR.97.6.569)
59. Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, Anderson NH, Fraser R & Connell JM. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999 33 703-707. (doi:10.1161/01.HYP.33.2.703)
60. Piaditis GP, Kaltsas GA, Androulakis II, Gouli A, Makras P, Papadogias D, Dimitriou K, Ragkou D, Markou A, Vamvakidis K et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clinical Endocrinology 2009 71 772-778. (doi:10.1111/j.1365-2265.2009.03551.x)
61. Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D, Vamvakidis K, Zografos G, Kontogeorgos G, Chrousos GP et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. European Journal of Clinical Investigation 2011 41 1227-1236. (doi:10.1111/j.1365-2362.2011.02531.x)
62. Ye P, Mariniello B, Mantero F, Shibata H & Rainey WE. G-proteincoupled receptors in aldosterone-producing adenomas: A potential cause of hyperaldosteronism. Journal of Endocrinology 2007 195 39-48. (doi:10.1677/JOE-07-0037)
63. Albiger NM, Sartorato P, Mariniello B, Iacobone M, Finco I, Fassina A & Mantero F. A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion? European Journal of Endocrinology 2011 164 405-412. (doi:10.1530/EJE-10-0879)
64. Gross MD, Grekin RJ, Gniadek TC & Villareal JZ. Suppression of aldosterone by cyproheptadine in idiopathic aldosteronism. New England Journal of Medicine 1981 305 181-185. (doi:10.1056/ NEJM198107233050401)
65. Mantero F, Rocco S, Opocher G, Armanini D, Boscaro M & DeAgostino D. Effect of ketanserin in primary aldosteronism. Journal of Cardiovascular Pharmacology 1985 7 (Suppl 7) S172-S175. (doi:10.1097/00005344-198500077-00048)
66. Perraudin V, Delarue C, Lefebvre H, Do Rego JL, Vaudry H & Kuhn JM. Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. Journal of Clinical Endocrinology and Metabolism 2006 91 1566-1572. (doi:10.1210/jc.2005-1453)
67. Rossi GP, Ganzaroli C, CesariM, Maresca A, Plebani M, Nussdorfer GG & Pessina AC. Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovascular Research 2003 57 277-283. (doi:10.1016/S0008-6363(02)00658-2)
68. Mansmann G, Lau J, Balk E, RothbergM,Miyachi Y & Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine Reviews 2004 25 309-340. (doi:10.1210/er.2002-0031)
69. Bernini G,Moretti A, Argenio G & Salvetti A. Primary aldosteronismin normokalemic patients with adrenal incidentalomas. European Journal of Endocrinology 2002 146 523-529. (doi:10.1530/eje.0.1460523)
70. Schwartz GL. Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness. Endocrinology and Metabolism Clinics of North America 2011 40 279-294, vii. (doi:10.1016/j.ecl.2011.02.001)
71. Schwartz GL & Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clinical Chemistry 2005 51 386-394. (doi:10.1373/clinchem.2004.041780)
72. Mulatero P, Monticone S, Bertello C, Mengozzi G, Tizzani D, Iannaccone A & Veglio F. Confirmatory tests in the diagnosis of primary aldosteronism. Hormone and Metabolic Research 2010 42 406-410. (doi:10.1055/s-0029-1246186)
73. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ,Wang TJ, Kathiresan S, OeDonnell CJ, Musone SL, Camargo AL et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007 49 846-856. (doi:10.1161/01.HYP.0000258554.87444.91)
74. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ & Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. New England Journal of Medicine 2004 351 33-41. (doi:10.1056/NEJMoa033263)
75. Lim PO, Dow E, Brennan G, Jung RT & MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. Journal of Human Hypertension 2000 14 311-315. (doi:10.1038/sj.jhh.1001013)
76. Loh KC, Koay ES, KhawMC,Emmanuel SC&YoungWF Jr. Prevalence of primary aldosteronismamong Asian hypertensive patients in Singapore. Journal of Clinical Endocrinology and Metabolism 2000 85 2854-2859. (doi:10.1210/jcem.85.8.6752)
77. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A & Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension 2003 42 161-165. (doi:10.1161/ 01.HYP.0000079505.25750.11)
78. Papanastasiou L, Markou A, Pappa T, Gouli A, Tsounas P, Fountoulakis S, Kounadi T, Tsiama V, Dasou A, Gryparis A et al. Primary aldosteronism in hypertensive patients: clinical implications and target therapy. European Journal of Clinical Investigation 2014 44 697-706. (doi:10.1111/eci.12286)
79. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006 232-238. (doi:10.1161/01.HYP.0000230444.01215.6a)
80. Westerdahl C, Bergenfelz A, Isaksson A, Nerbrand C & Valdemarsson S. Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area. Scandinavian Journal of Primary Health Care 2011 29 57-62. (doi:10.3109/02813432.2011.554015)
81. Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, Beuschlein F & Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. European Journal of Endocrinology 2004 150 329-337. (doi:10.1530/eje.0.1500329)
82. Ribeiro MJ, Figueiredo Neto JA, Memoria EV, Lopes MC, Faria MS, Salgado FN & Oliveira TC. Prevalence of primary hyperaldosteronism in a systemic arterial hypertension league. Arquivos Brasileiros de Cardiologia 2009 92 39-45. (doi:10.1590/S0066-782X2009000100007)
83. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro Hypertension 2007 50 447-453. (doi:10.1161/ HYPERTENSIONAHA.106.086116)
84. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012 125 e2-e220. (doi:10.1161/CIR.0b013e31823ac046)
85. Xanthakis V & Vasan RS. Aldosterone and the risk of hypertension. Current Hypertension Reports 2013 15 102-107. (doi:10.1007/ s11906-013-0330-y)
86. Zennaro MC, Rickard AJ & Boulkroun S. Genetics of mineralocorticoid excess: An update for clinicians. European Journal of Endocrinology 2013 169 R15-R25. (doi:10.1530/EJE-12-0813)
87. Ducher M, Mounier-Vehier C, Baguet JP, Tartiere JM, Sosner P, Regnier-Le CS, Perez L, Fourcade J, Jabourek O, Lejeune S et al. Aldosterone-to-renin ratio for diagnosing aldosterone-producing adenoma: A multicentre study. Archives of Cardiovascular Diseases 2012 105 623-630. (doi:10.1016/j.acvd.2012.07.006)
88. Levy DG, Rocha R & Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. Journal of Clinical Endocrinology and Metabolism 2004 89 2736-2740. (doi:10.1210/jc.2003-032149)
89. Savoia C, Touyz RM, Amiri F & Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008 51 432-439. (doi:10.1161/ HYPERTENSIONAHA.107.103267)
90. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H & Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 49 839-845. (doi:10.1161/ 01.HYP.0000259805.18468.8c)
91. Iqbal J, Andrew R, Cruden NL, Kenyon CJ, Hughes KA, Newby DE, Hadoke PW & Walker BR. Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist. Journal of Clinical Endocrinology and Metabolism 2014 99 915-922. (doi:10.1210/jc.2013-2049)
92. Achelrod D, Wenzel U & Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. American Journal of Hypertension 2015 28 355-3961. (doi:10.1093/ajh/hpu151)
93. Funder JW. Primary aldosteronism: Are we missing the wood for the trees? Hormone and Metabolic Research 2012 44 251-253. (doi:10.1055/ s-0031-1301281)
94. Macfarlane DP, Yu N & Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet. Diabetes & Endocrinology 2013 1 329-340. (doi:10.1016/S2213-8587 (13)70083-4)
95. KaltsasG,Chrisoulidou A, Piaditis G, Kassi E&ChrousosG.Current status and controversies in adrenal incidentalomas. Trends in Endocrinology and Metabolism 2012 23 602-609. (doi:10.1016/j.tem.2012.09.001)
96. Brooks RV, Felix-Davies D, Lee MR & Robertson PW. Hyperaldosteronism from adrenal carcinoma. BMJ 1972 1 220-221. (doi:10.1136/ bmj.1.5794.220)
97. Medeau V, Moreau F, Trinquart L, Clemessy M, Wemeau JL, Vantyghem MC, Plouin PF & Reznik Y. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: A comparison with hypertensive cases. Clinical Endocrinology 2008 69 20-28. (doi:10.1111/j.1365-2265.2008.03213.x)
98. Pappa T, Papanastasiou L, Kaltsas G, Markou A, Tsounas P, Androulakis I, Tsiavos V, Zografos G, Vamvakidis K, Samara C et al. Pattern of adrenal hormonal secretion in patients with adrenal adenomas: the relevance of aldosterone in arterial hypertension. Journal of Clinical Endocrinology and Metabolism 2012 97 E537-E545. (doi:10.1210/jc.2011-2874)
99. Stowasser M, Huggard PR, Rossetti TR, Bachmann AW & Gordon RD. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I. Journal of Clinical Endocrinology and Metabolism 1999 84 4031-4036. (doi:10.1210/jcem.84.11.6159)
100. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D & Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. Journal of Clinical Endocrinology and Metabolism 2005 90 5070-5076. (doi:10.1210/jc.2005-0681)